[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"family-members\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:family-members":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,48,73,100,134,169,196,222,245,277,310,339,363],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100498929","gamma-light-and-sound-stimulation-to-prevent-dementia-in-cognitively-normal-people-at-risk-for-alzheimers-disease-100498929",false,"NCT05776641","Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease","Prevention of Alzheimer's Disease Using Gamma Entrainment","Inclusion Criteria:\n\n1. Between 55 - 90 years of age, inclusive.\n2. Immediate family history of Alzheimer's disease.\n3. Mini-Mental State Exam (MMSE) score of 27 or greater at baseline or expected score range for cognitively normal adjusted for education level.\n4. Clinical Dementia Rating Global Score of 0 at baseline.\n5. Delayed Recall score on the Logical Memory IIa subtest of 8 to 15 at baseline or expected score range for cognitively normal adjusted for education level.\n6. Low serum amyloid levels at baseline.\n7. Elevated fibrillar amyloid using 11C PiB PET at baseline between 20 - 70 CL.\n8. Willing and able to undergo MRI brain and PET brain scans.\n9. Adequate visual and auditory acuity to allow for neuropsychological testing.\n10. Able to comply with neuropsychological testing and other study procedures in opinion of site PI.\n11. Willing and able to complete baseline assessments, and willing to participate in 13-month study protocol.\n12. Willing to provide blood samples at specified timepoints. Willing to consider contributing CSF samples at specified timepoints, if asked.\n\nExclusion Criteria:\n\n1. MRI contraindications, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body.\n2. High myopia \\\u003C -7 diopters, or untreated cataracts that affect vision.\n3. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.\n4. For subjects agreeing to undergo lumbar punctures, history of bleeding disorders or laboratory results indicating low platelet levels are exclusionary for the procedure.\n5. Concomitant medications:\n\n   1. Treatment with NMDA antagonists.\n   2. For subjects undergoing lumbar puncture, current use of warfarin or similar anti-coagulants is exclusionary for the procedure.\n6. Clinical conditions:\n\n   1. History of seizure or medical diagnosis of epilepsy.\n   2. Female subjects who are pregnant or currently breastfeeding.\n   3. History of severe allergic or anaphylactic reactions.\n   4. Longstanding premorbid history (i.e., longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed.\n   5. Neurodegenerative disorder associated with cognitive impairment.\n   6. Renal disease.\n7. MR imaging findings such as stroke, tumor, leukoencephalopathy that could preclude meaningful analyses of clinical and imaging data in the opinion of the site PI, such as:\n\n   1. Severe leukoencephalopathy seen on MRI.\n   2. Relevant structural abnormality (i.e., normal pressure or obstructive hydrocephalus, hypoxic ischemic lesions, hemorrhages, tumors, malformations).\n   3. Cerebral amyloid angiopathy, evidenced by T2\\* or other susceptibility weighted-MRI.\n8. Laboratory findings, if known (study does not perform testing) suggestive of systemic illness such as renal disease.\n9. Site investigator's discretion, if s\u002Fhe feels the subject cannot complete sufficient key study procedures. Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the Project Director.",true,"ALL","55 Years","90 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. Gamma waves are important for memory, and in patients with AD, there are fewer gamma waves in the brain. The Tsai lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. A light and sound device was developed for humans that stimulates the brain at 40Hz that can be used safely at home. The goal of this study is to see if using this device can prevent dementia in people who are at risk for developing Alzheimer's disease.",[28,29],"Alzheimer Disease","Family Members",[31,32,33,34],"Cognitively normal","Alzheimer's disease","Gamma","Amyloid","RECRUITING","2026-06-16",{"date":38,"type":39},"2026-06-18","ACTUAL",{"date":41,"type":39},"2024-06-21",{"date":43,"type":22},"2027-05",{"name":45,"class":46},"Massachusetts General Hospital","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100523024","motivational-interviewing-to-enhance-advance-care-planning-for-older-adults-and-caregivers-after-emergency-visits-100523024","NCT06090240","Motivational Interviewing to Enhance Advance Care Planning for Older Adults and Caregivers After Emergency Visits","Maximizing Teachable Moments: Motivational Interviewing (MI) to Enhance Advance Care Planning (ACP) for Older Adults and Caregivers After Emergency Visits - A Mixed-Method Randomized Controlled Trial","The target group will be dyads comprising older adults who have had ER visits within the previous six months and their family caregivers. A dyad is defined as one older adult and one primary family caregiver of the older adult.\n\nFor older adults:\n\nInclusion Criteria:\n\n* Aged 65 or older\n* At least one episode of ER visit in the last six months\n* Has a family caregiver to be present during the intervention\n* Able to communicate in Chinese\n\nExclusion Criteria:\n\n* Has completion of an AD\n* Moderate to severe cognitive impairment or diagnosis of dementia, as identified in health records\n* Communication problems (e.g., deafness or aphasia)\n\nFor family caregivers:\n\nInclusion Criteria:\n\n* Aged 18 or above\n* Immediate or extended family member or friend nominated by an eligible older adult participant as primary caregiver\n* Able to communicate in Chinese\n\nExclusion Criteria:\n\n* Moderate to severe cognitive impairment\n* Communication problems (e.g., deafness or aphasia)",{"count":56,"type":22},300,[25],"This study aims to evaluate the effectiveness of a motivational interviewing (MI) intervention in enhancing advance care planning (ACP) among older adults who have visited the Emergency Room (ER) in the past six months and their family caregivers. The main question it aims to answer is: The effectiveness of the MI-based ACP intervention implemented within six months of an ER visit on improving older adults' advance directives (AD) completion rate.\n\nCompared to participants in the control group who will only receive a self-education booklet, participants in the intervention group will receive a motivational interview educational intervention to see the effectiveness of an MI-based ACP intervention implemented within six months following an emergency room visit regarding the completion of AD for older adults.",[60,61,62,29],"Older Adults","Advance Care Planning","Advance Directives","2026-05-28",{"date":65,"type":39},"2026-06-02",{"date":67,"type":39},"2023-12-14",{"date":69,"type":22},"2027-07-31",{"name":71,"class":46},"The University of Hong Kong",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":16,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100629712","the-preventive-risk-outreach-and-cascade-testing-100629712","NCT07478237","The Preventive Risk Outreach And Cascade Testing","The Preventive Risk Outreach and Cascade Testing (PROACT)","PROACT","Inclusion Criteria - Probands\n\n1. Age ≥ 18 years old.\n2. Known to carry a pathogenic or likely pathogenic variant in a gene included in the 2024 current Color Health Cancer Panel Test.\n3. Have at least one (1) first- or second-degree relative who is living in the United States and has not yet had germline genetic testing.\n\nExclusion Criteria - Probands\n\n1\\. Unable to read and write English or Spanish.\n\nInclusion Criteria - Relatives\n\n1. Age ≥ 18 years old.\n2. Resides in the United States.\n\nExclusion Criteria - Relatives\n\n1. Completed genetic testing by a clinician within the last 5 years that included the pathogenic or likely pathogenic variant.\n2. Not a first- or second-degree relative of the proband.","18 Years",{"count":83,"type":22},400,[25],"The goal of this clinical trial is to learn whether a new online program developed by the research team is able to help families learn about family cancer risk and how to reduce this risk, as well as help interested family members get low-cost, at-home genetic testing for cancer risk.",[87,29],"Genetic Predisposition",[89],"Cascade genetic testing","NOT_YET_RECRUITING","2026-05-11",{"date":93,"type":39},"2026-05-14",{"date":95,"type":22},"2026-06",{"date":97,"type":22},"2029-12",{"name":99,"class":46},"Stanford University",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":16,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":118,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100632905","recovery-inspired-support-engagement-rise-pilot-100632905","NCT07519759","Recovery Inspired Support Engagement (RISE) Pilot","(RISE)","Inclusion Criteria:\n\n* Inclusion Criteria for Support Persons:\n\n  * Ages 18+.\n  * Having a loved one who participated in an inpatient or residential substance use disorder program in the past 30 days, as reported by loved one, support person, clinician, or chart review.\n  * Interest in supporting the loved one's recovery from substance use.\n  * At least 4 days per month virtual or in-person contact per month with the loved one.\n  * Access to a computer with internet or mobile phone with video conferencing capabilities.\n  * Ability to provide written informed consent.\n  * Speak and read English.\n* Inclusion Criteria for Loved Ones:\n\n  * Ages 18+.\n  * Participated in an inpatient or residential substance use disorder program in the past 30 days, as reported by self, support person, clinician, or chart review.\n  * At least 4 days per month virtual or in-person contact per month with the support person.\n  * Access to a computer with internet or mobile phone with video conferencing capabilities.\n  * Ability to provide written informed consent.\n  * Speak and read English.\n\nExclusion Criteria:\n\n* Exclusion Criteria for Support Persons:\n\n  * DSM-5 moderate or severe substance use disorder in the past year.\n  * History of domestic violence with the loved one that would interfere with the ability to safely follow through with the intervention plan.\n  * Psychiatric, cognitive, or medical impairments that would interfere with the ability to follow through with the intervention plan.\n  * Prior participation of a support person of the loved one in an ITC-related research study.\n  * Significant prior experience with ITC or CRAFT (e.g., having completed an ITC-related training workshop or course prior to study enrollment)\n* Exclusion Criteria for Loved Ones: N\u002FA",{"count":108,"type":22},18,[25],"The goal of this clinical trial is to learn if a 1-on-1 support program is easy to complete and acceptable for people supporting loved ones who have recently received treatment for substance use. The main questions it aims to answer are:\n\nHow many people complete the program? How satisfied are people with the program?\n\nParticipants will:\n\nComplete weekly telehealth sessions for 12 weeks Complete surveys\u002Finterviews at the beginning, in the middle (\\~week 6), at the end of the program (\\~week 12), and 12-weeks after the end of the program Complete a focus group or interview",[112,29,113,114,115,116,117],"Support Persons","Chosen Family","Romantic Partners","Friends","Caregivers","Substance Use Disorders",[112,115,117,119,120,121,122,123,124,114,113,29,116],"Alcohol","Substance Use (Drugs, Alcohol)","Social Support","Recovery","Invitation to Change","ITC","2026-04-23",{"date":127,"type":39},"2026-04-28",{"date":129,"type":22},"2026-07-01",{"date":131,"type":22},"2028-02-28",{"name":133,"class":46},"Mclean Hospital",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":142,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":156,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100510689","evaluating-novel-healthcare-approaches-to-nurturing-and-caring-for-hospitalized-elders-100510689","NCT05929703","Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders","Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders (ENHANCE)","ENHANCE","Inclusion Criteria:\n\n* Provision of informed consent\n* At least 70 years of age\n* Anticipated length of hospital stay at least 72 hours\n* Family member or care partner available to be on-site in the hospital\n* At least one delirium risk factor (e.g., cognitive or functional impairment, dehydration, vision or hearing impairment)\n* Evaluable cognitive function at baseline (i.e., ability to complete baseline cognitive function assessment)\n\nExclusion Criteria:\n\n* Delirium on admission\n* Unable to communicate verbally (e.g., coma, mechanical ventilation)\n* Unable to participate fully in interventions (e.g., terminal condition, advanced dementia)\n* Staff safety concerns (e.g., violent behavior)\n* Cardiac or intracranial surgery (due to competing causes of delirium)","70 Years",{"count":144,"type":22},1900,[25],"The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are the following:\n\n1. To compare the effectiveness of FAM-HELP and HELP in reducing both the incidence of delirium and its severity.\n2. To compare the effectiveness of FAM-HELP and HELP in improving patient- and family-reported outcomes.\n3. To explore the implementation context, process, and outcomes of the FAM-HELP program in diverse hospital settings.",[148,149,150,28,151,152,29,153,154,155],"Delirium","Neurocognitive Disorders","Mild Cognitive Impairment","Aging","Family Support","Caregiver Burden","Implementation Science","Patient Satisfaction",[148,157,158,154],"Clinical Trial","Comparative Effectiveness Research","2026-03-20",{"date":161,"type":39},"2026-03-24",{"date":163,"type":39},"2023-12-04",{"date":165,"type":22},"2027-08",{"name":167,"class":46},"University of Michigan",7,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":195},"100588719","family-engagement-strategy-for-coordinated-specialty-care-100588719","NCT06945055","FAmily Engagement Strategy for Coordinated Specialty Care","Integration of a Culturally Responsive Family Peer Delivered Engagement Strategy in Coordinated Specialty Care","FAMES","Family Member \u002F Support Person Inclusion Criteria:\n\n* Family member\u002Fsupport person of an individual enrolled in coordinated specialty care services for less than or equal to 6 months.\n* 18 years of age or older.\n* During the active implementation period (FAMES) did not participate in the attention control condition.\n\nExclusion Criteria:\n\n* If they do not understand the consent process.\n* If they do not speak and\u002For understand English or Spanish.\n\nPrimary Service User Inclusion Criteria\n\n* enrolled in coordinated specialty care services for less than or equal to 6 months.\n* 15 years of age or older.\n* Has a family member\u002Fsupport person willing to engage in the study. during the active implementation period (FAMES) did not participate in the attention control condition.\n\nExclusion Criteria\n\n* if they do not understand the consent process\n* If they do not speak and\u002For understand English or Spanish",{"count":178,"type":22},900,[25],"Family members\u002Fsupport persons' engagement in mental health services has been linked to reduced burden and stress and improves engagement and outcomes in individuals in the early stages of psychosis. The goal of FAMES is to address low family member\u002Fsupport person engagement in services. FAMES will also address disparities in coordinated specialty care (CSC) by using a culturally responsive family engagement strategy to be delivered by family peers.",[29,182],"Implementation",[184,185,186],"early psychosis","family peer","engagement","2026-02-19",{"date":189,"type":39},"2026-02-23",{"date":191,"type":39},"2025-03-01",{"date":97,"type":22},{"name":194,"class":46},"Washington State University",4,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":16,"sex":17,"minAge":81,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":4},"100624167","meop---multidimensional-evaluations-in-oncological-psychiatry-100624167","NCT07406113","MEOP - Multidimensional Evaluations in Oncological Psychiatry","MEOP","Inclusion Criteria:\n\n* For cases: any subject affected by cancer with a comorbid psychiatric disorder (further defined as \"cases\") or any first-degree relative of a subject of a \"case\" (i.e., i.e. a fist-degree relative of a subject affected by cancer and a psychiatric disorder). These first-degree relatives will be defined as \"cases-rel\".\n* For controls: a) Subjects with cancer who will undergo a consultation in the Clinical and Emergency Psychiatry Unit of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS but who do not show any psychiatric symptoms (further defined as \"oncology-controls\"); b) subjects without cancer who will undergo a psychiatric evaluation in the Clinical and Emergency Psychiatry Unit and present psychiatric symptoms (further defined as \"psy-controls\"); c) Subjects without cancer and with any suspected psychiatric disorder who will undergo a psychiatric evaluation in the Clinical and Emergency Psychiatry Unit and who are not diagnosed with any relevant psychiatric symptoms after the evaluation (further defined as \"healthy controls\"); d) First-degree relatives of \"oncology-controls\", \"psy-controls\" and \"healthy controls\" (further defined as \"control-rel\").\n* Age between 18 and 75 years.\n* Capability of providing written informed consent.\n\nExclusion Criteria:\n\n* Severe cognitive impairment or inability to provide written informed consent.\n* Severe unstable neurological disorders, such as traumatic brain injury, Alzheimer's Disease or dementia.\n* Inability to perform psychiatric or neuropsychological evaluations.","75 Years",{"count":205,"type":22},2000,"OBSERVATIONAL","Cancer is among the leading causes of morbidity and mortality worldwide, profoundly affecting patients' lives at every level, and its psychological and psychiatric impacts remain a major concern. Psychiatric disorders are frequently observed in cancer patients. Nevertheless, they were also underdiagnosed, with a consequent undermining possible interventions. Still, psychiatric disorders in cancer patients are not merely secondary complications but may actively contribute to poor oncological outcomes.\n\nThe pathophysiology of cancer-related psychiatric disorders is multifactorial and is related to several neuropsychological and neurobiological factors. Specifically, the production of cytokines associated with cancer appears to play a role in the development of depression. Tumours trigger an inflammatory response that leads to the release of pro-inflammatory cytokines. These cytokines influence central nervous system function and disrupt the regulation of the HPA axis, contributing to psychological symptoms such as depression, fatigue, sleep disturbances, and appetite loss.\n\nMoreover, psychiatric symptoms in cancer patients are often accompanied by neuropsychological alterations including deficits in memory, executive function, and attention. Compared to other individuals with psychiatric disorders, cancer patients may experience more severe cognitive impairments which can be exacerbated by cancer treatments, including surgery, chemotherapy, and radiotherapy. These treatments stimulate cytokine production by nearby non-cancerous cells and immune cells activated in response to treatment-induced cell death, thereby driving systemic inflammation.\n\nCancer profoundly affects not only patients but also their families, who often bear the emotional and caregiving burden. Being close to a loved one with cancer can lead to significant psychological distress, including anxiety and depression, among family members and caregivers. The ripple effects of this burden underscore the need for a holistic approach to mental health in oncology.\n\nGiven the background presented so far, identifying and managing psychiatric comorbidities in oncological patients and their families is crucial. This multifaceted interplay between cancer and psychiatric disorders necessitates a comprehensive, interdisciplinary approach to understanding, diagnosing, and treating these conditions effectively.",[209,210,211,212,29],"Psychiatric Disorder","Cognition Disorder","Treatment Compliance","Adverse Drug Event","2026-02-09",{"date":215,"type":39},"2026-02-12",{"date":217,"type":22},"2026-01-30",{"date":219,"type":22},"2036-01-29",{"name":221,"class":46},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":4},"100622930","families-experiencing-cancer---support-to-prevent-cancer-related-illness-100622930","NCT07390019","Families Experiencing Cancer - Support to Prevent Cancer-related Illness","FamCASP","Inclusion Criteria:\n\nParticipants are adult (≥18years) family members to patients diagnosed with CRC. Inclusion criteria are the ability to read and understand Swedish and having access to a computer, tablet or mobile phone to access the digital screening tool as well as the study information.\n\nExclusion Criteria:\n\n\\-",{"count":230,"type":22},800,[25],"In this planned project, we aim to evaluate the FamCASP model and the digital screening tool SCa-N as an intervention within routine cancer care. An expected outcome of FamCASP is an increase in family health as expressed in lower levels of psychological distress, improved coping strategies and family climate and a decrease in unmet needs as measured by family members' self-reports as well as their descriptions during interviews. Hence, the specific aims are to:\n\nI. Describe differences in psychological distress, coping strategies, family climate and unmet needs between baseline and follow-up in family members receiving support according to the FamCASP model in outpatient cancer clinics and to explore whether or not there are differences between family members receiving support and those who do not receive support.\n\nII. Describe family members' experiences of receiving support according to the FamCASP model.\n\nIII. Describe family members' experiences of interacting with the digital tool.",[234,29,235],"Cancer","Support, Family","2026-01-29",{"date":238,"type":39},"2026-02-05",{"date":240,"type":22},"2026-02-02",{"date":242,"type":22},"2032-12-30",{"name":244,"class":46},"Malmö University",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":251,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":256,"conditions":257,"keywords":261,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":195},"100477671","supporting-patients-by-family-education-in-psychotic-illness-a-prospective-cohort-study-100477671","NCT05500001","Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study","Inclusion Criteria:\n\n* Young adult service user is aged 17-27 at time of recruitment\n* Young adult service user has had an admission or discharge from an Alberta Health Services or Covenant Health psychiatric unit for psychosis in the Edmonton Zone within previous 12-months\n\nExclusion Criteria:\n\n* Not proficient in English\n* Young adult service user has NOT had an admission or discharge from an Alberta Health Services or Covenant Health psychiatric unit for psychosis in the Edmonton Zone within previous 12-months","17 Years","27 Years",{"count":254,"type":22},113,[25],"Background: A lack of education, resources, and support for family carers of young adults with psychotic illnesses leaves them ill-equipped to support their loved one. Although family support groups exist, few groups offer evidence-based, skills-focused, psychoeducation taught by certified professionals and provided on a public-health level. By equipping families with skills and knowledge, public healthcare harnesses a powerful ally to maintain community stabilization.\n\nAims: The primary study goal is to implement a psychoeducation intervention for family carers supporting young adults with psychosis to reduce family burden and foster community stabilization of service users.\n\nMethods: A longitudinal pre-post design will be used to assess the long-term effectiveness of the psychoeducation intervention for family carers supporting a young adult with psychosis on service utilization and functional indexes. Nine expert-reviewed, and family peer-informed psychoeducation modules are administered in 2-hour sessions over 9 weeks to family carers.\n\nConclusion: Presenting the novel approach of an expert-reviewed, peer-informed psychoeducation intervention for family carers, with a focus on knowledge and skill development, the researchers contribute to literature and best practice in patient and family-centered care.",[258,29,259,260],"Psychotic Disorders","Anosognosia","Paranoia",[262,263,264,265,266,267],"Young Adult","Psychosis","Family Psychoeducation","Family Burden","Acceptance and Commitment Therapy","LEAP","2025-11-14",{"date":270,"type":39},"2025-11-18",{"date":272,"type":39},"2022-09-01",{"date":274,"type":22},"2026-09-01",{"name":276,"class":46},"University of Alberta",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":17,"minAge":203,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":286,"conditions":287,"keywords":292,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":306,"leadSponsor":308,"locationsCount":4},"100595707","the-vip3-very-old-intensive-care-patients-study-family-involvement-in-treatment-decisions-for-old-icu-patients-100595707","NCT07035951","The VIP3 (Very Old Intensive Care Patients) Study: Family Involvement in Treatment Decisions for Old ICU Patients","The VIP-3 (Very Old Intensive Care Patients) Study: Decision-making in the Older Intensive Care Unit (ICU) Patient: How Are Family Meetings Implemented Across Diverse Cultures in Europe?","VIP3","Inclusion Criteria:\n\n* Patients admitted to the Intensive Care Unit (ICU) of participating centres\n* Age 75 years and above\n* Expected Length of stay (LOS) \\> 3 days\n\nExclusion Criteria:\n\n* Refusal to participate\n* Limitation of treatment upon ICU arrival (other than Cardiopulmonary Resuscitation-CPR)\n* Planned admission",{"count":205,"type":22},"The demographics of the global population is changing with increasing numbers of elderly and co-morbid patients. As a result, more elderly patients will be admitted to the Intensive Care Unit (ICU), which will bring several ethical challenges. It is for this reason the investigators have chosen to focus on this historically neglected and important patient population.\n\nLittle is known about how family meetings are implemented in ICUs in Europe and other parts of the world. However, these meetings contribute to building trust between the family and the ICU team. They are a crucial component for planning and conducting a time limited trials as they provide the opportunity for shared-decision making with the ICU team and with other stakeholders.\n\nThe investigators plan to determine the current practice of communication between ICU staff and patients and their relatives. The investigators expect to find a substantial variation in approaches to family meetings. This information may then help design and further investigate targeted interventions enabling shared decision-making focused on family and patient values.\n\nThe investigators research aim is to to investigate whether Family meetings are used in ICUs across Europe and other regions and, if so, how they are conducted and the influence on patient-centred outcome measures.",[29,288,289,290,291],"Critical Illness","Frailty","Communication","Patient Preference",[293,294,295,296,297,298,299,300,301],"Elderly","Critical illness","communication","frailty","family meetings","Intensive care","critical care","shared decision making","patient preference","2025-06-16",{"date":304,"type":39},"2025-06-25",{"date":302,"type":22},{"date":307,"type":22},"2026-12",{"name":309,"class":46},"St George's, University of London",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":23,"phases":320,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":72},"100561279","clinical-trial-recruitment-and-retention-strategies-for-family-members-in-the-icu-100561279","NCT06588101","Clinical Trial Recruitment and Retention Strategies for Family Members in the ICU","Clinical Trial Recruitment and Retention Strategies for Family Members in the Intensive Care Unit: A Study Within A Trial Randomized Design","SWAT","Inclusion Criteria:\n\n* Has family member admitted to an intensive care unit.\n* Expected hospital stay \\> 48 hours\n* Able to participate in English or French\n\nExclusion Criteria:\n\n* Has another family member participating in the trial\n* Repeat admissions within the study period",{"count":319,"type":22},160,[25],"There is a need to identify strategies that improve the conduct of clinical trials involving family members of intensive care unit (ICU) patients. The purpose of the present study is to evaluate recruitment and retention strategies for clinical trials involving family members of ICU patients. 4 strategies (2 recruitment and 2 retention) will be tested. Investigators will integrate the strategies into three existing studies that involve family members of ICU patients. Participants will be randomized using a 2x2 factorial design. The co-primary outcomes are recruitment percentage (participants enrolled\u002Fparticipants approached) and retention percentage (participants completing follow-up\u002Fparticipants enrolled).",[29,323,324,325,326,327,328,329],"Recruitment","Clinical Study","Retention","Recruitment of Participants","Study Enrollment","Retention of Participants","Compensation Incentives","2025-05-29",{"date":332,"type":39},"2025-06-04",{"date":334,"type":39},"2024-05-01",{"date":336,"type":22},"2026-12-31",{"name":338,"class":46},"Lady Davis Institute",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":16,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":23,"phases":348,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":72},"100461137","family-peer-navigator-for-early-psychosis-for-black-families-100461137","NCT05284721","Family Peer Navigator for Early Psychosis for Black Families","A Family Peer Navigator Model to Increase Access and Initial Engagement in Coordinated Specialty Care Programs Among Black Families","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Identifies as Black\u002FAfrican American\n3. Loved one who meets criteria for risk of psychosis with a total score of ≥ 3 on the Prodromal Questionnaire- Brief Version\n\nExclusion Criteria:\n\n1. Family members who cannot understand the consent process\n2. Non-English speaking adults\n3. Black\u002FAfrican American families referred to coordinated specialty care and who have already been determined eligible for services by providers.",{"count":347,"type":22},50,[25],"Building upon formative research, this mixed methods study will be conducted in three phases to develop, refine, and pilot-test a multi-component Family Peer Navigator model designed to increase access to and initial engagement in coordinated specialty care for early psychosis among Black\u002FAfrican American families.",[29],[352,353,354],"Black\u002FAfrican American","Early Psychosis","Access and Engagement","2025-04-17",{"date":357,"type":39},"2025-04-23",{"date":359,"type":39},"2023-01-01",{"date":361,"type":22},"2025-09-30",{"name":194,"class":46},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":16,"sex":17,"minAge":370,"maxAge":251,"enrollmentInfo":371,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":72},"100499173","genetic-frontotemporal-dementia-initiative-for-neurodevelopment-100499173","NCT05779813","Genetic Frontotemporal Dementia Initiative for Neurodevelopment","GENFI-NeuroDev","Inclusion Criteria:\n\n1. Written informed consent must be obtained and documented (from the participant and their substitute decision maker). This can be obtained in person or remotely.\n2. Youths between the ages of 9 and 16 inclusive at time of enrollment, followed until age 17.\n3. Youths must have a 1st or 2nd degree biological relative who has participated (past or present) in the Genetic Frontotemporal Dementia Initiative (GENFI) study or with genetic FTD (i.e. a known mutation in biological parent or grandparent).\n4. Parent(s)\u002Fguardian deem appropriate to participate.\n5. Must have a study partner who can participate as required in the protocol (provide corroborative information). Study partner must have regular contact with the participant and must be parent\u002Fguardian of this participant.\n6. Must have age-appropriate awareness that FTD runs in their family as determined by local PI.\n\nExclusion Criteria:\n\n1. Current structural brain abnormality affecting cognition or behaviour not thought to be possibly related to genetic FTD that would prevent completion of study assessments (such as brain tumor, stroke, hydrocephalus).\n2. Other concerns that participation in the study may not be in the best interest of the youth or parent, as raised by the participant's parent\u002Fguardian\u002Fprimary care provider, local site PI or psychologist.\n3. Lack of study partner.\n4. For MRI: meeting any MRI incompatible criteria. Note: Participants may opt to decline MRI scans and complete the other measures.","7 Years",{"count":21,"type":22},"This is an international multi-centre cohort study of first and second degree family members of individuals who carry Frontotemporal Dementia (FTD) mutations in MAPT, GRN or C9ORF72 repeat expansions for youths between the ages 9-17.",[374,29],"Frontotemporal Dementia","2025-03-31",{"date":377,"type":39},"2025-04-03",{"date":379,"type":39},"2023-03-31",{"date":381,"type":22},"2035-03",{"name":383,"class":46},"Western University"]